"Nov. 6, 2012 -- Exercise helps put people with Parkinson's disease on a path to better health, a new study shows.
All Parkinson's patients reach a point in their disease where they begin to have trouble walking. Typically, a person st"...
- Patient Information:
Details with Side Effects
The most common adverse reactions reported with carbidopa-levodopa have included dyskinesias, such as choreiform, dystonic, and other involuntary movements and nausea.
The following other adverse reactions have been reported with carbidopa-levodopa:
Nervous System/Psychiatric: Psychotic episodes including delusions, hallucinations, and paranoid ideation, neuroleptic malignant syndrome (see WARNINGS), bradykinetic episodes ("on-off' phenomenon), confusion, agitation, dizziness, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, increased libido. Convulsions also have occurred; however, a causal relationship with carbidopa-levodopa has not been established.
Respiratory: Dyspnea, upper respiratory infection.
Urogenital: Urinary tract infection, urinary frequency, dark urine.
Laboratory Tests: Decreased hemoglobin and hematocrit; abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase, bilirubin, blood urea nitrogen (BUN), Coombs' test; elevated serum glucose; white blood cells, bacteria, and blood in the urine.
Other adverse reactions that have been reported with levodopa alone and with various carbidopa-levodopa formulations, and may occur with Stalevo® (carbidopa, levodopa and entacapone) are:
Musculoskeletal: Leg pain.
Nervous System/Psychiatric: Ataxia, extrapyramidal disorder, failing, anxiety, gait abnormalities, nervousness, decreased mental acuity, memory impairment, disorientation, euphoria, blepharospasm (which may be taken as an early sign of excess dosage; consideration of dosage reduction may be made at this time), trismus, increased tremor, numbness, muscle twitching, activation of latent Horner's syndrome, peripheral neuropathy.
Respiratory: Pharyngeal pain, cough.
Laboratory Tests: Decreased white blood cell count and serum potassium; increased serum creatinine and uric acid; protein and glucose in urine.
The most commonly observed adverse events ( > 5%) in the double-blind, placebo-controlled trials of entacapone (N=1003) associated with the use of entacapone alone and not seen at an equivalent frequency among the placebo-treated patients were: dyskinesia/hyperkinesia, nausea, urine discoloration, diarrhea, and abdominal pain.
Approximately 14% of the 603 patients given entacapone in the double-blind, placebo-controlled trials discontinued treatment due to adverse events compared to 9% of the 400 patients who received placebo. The most frequent causes of discontinuation in decreasing order are: psychiatric reasons (2% vs. 1%), diarrhea (2% vs. 0%), dyskinesia/hyperkinesia (2% vs. 1%), nausea (2% vs. 1%), abdominal pain (1% vs. 0%), and aggravation of Parkinson's disease symptoms (1% vs. 1%).
Adverse Event Incidence in Controlled Clinical Studies of Entacapone
Table 5 lists treatment emergent adverse events that occurred in at least 1% of patients treated with entacapone participating in the double-blind, placebo-controlled studies and that were numerically more common in the entacapone group, compared to placebo. In these studies, either entacapone or placebo was added to carbidopa-levodopa (or benserazide-levodopa).
Table 5: Summary of Patients With Adverse Events After Start
of Trial Drug Administration At Least 1% in Entacapone Group and > Placebo
| SYSTEM ORGAN CLASS
(n = 603)
% of patients
(n = 400)
% of patients
|SKIN AND APPENDAGES DISORDERS|
|MUSCULOSKELETAL SYSTEM DISORDERS|
|CENTRAL & PERIPHERAL NERVOUS SYSTEM DISORDERS|
|SPECIAL SENSES, OTHER DISORDERS|
|GASTROINTESTINAL SYSTEM DISORDERS|
|Gastrointestinal Disorders NOS||1||0|
|RESPIRATORY SYSTEM DISORDERS|
|PLATELET, BLEEDING & CLOTTING DISORDERS|
|URINARY SYSTEM DISORDERS|
|BODY AS A WHOLE - GENERAL DISORDERS|
|RESISTANCE MECHANISM DISORDERS|
The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures do, however, provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse events observed in the population studied.
Effects of Gender and Age on Adverse Reactions
No differences were noted in the rate of adverse events attributable to entacapone alone by age or gender.
Drug Abuse And Dependence
Controlled substance class: Stalevo (carbidopa, levodopa and entacapone) ® (carbidopa, levodopa and entacapone) is not a controlled substance.
Physical and psychological dependence: Stalevo (carbidopa, levodopa and entacapone) ® has not been systematically studied, in animal or humans, for its potential for abuse, tolerance or physical dependence. In premarketing clinical experience, carbidopa-levodopa did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. However, there are rare postmarketing reports of abuse and dependence of medications containing levodopa. In general, these reports consist of patients taking increasing doses of medication in order to achieve a euphoric state.
Read the Stalevo (carbidopa, levodopa and entacapone) Side Effects Center for a complete guide to possible side effects
Caution should be exercised when the following drugs are administered concomitantly with Stalevo (carbidopa, levodopa and entacapone) ® .
Anti-hypertensive agents: Symptomatic postural hypotension has occurred when carbidopa-levodopa was added to the treatment of patients receiving antihypertensive drugs. Therefore, when therapy with Stalevo (carbidopa, levodopa and entacapone) ® is started, dosage adjustment of the antihypertensive drug may be required.
MAO inhibitors: For patients receiving nonselective MAO inhibitors, see CONTRAINDICATIONS. Concomitant therapy with selegiline and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone.
Tricyclic antidepressants: There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa.
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid: Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
Phenytoin and papaverine: The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with carbidopa-levodopa should be carefully observed for loss of therapeutic response.
Iron salts: Iron salts may reduce the bioavailability of levodopa, carbidopa and entacapone. The clinical relevance is unclear.
Metoclopramide: Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
Drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase (probenecid, cholestyramine, erythromycin, rifampicin, ampicillin and chloramphenicol): As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone. These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol).
Pyridoxine: Stalevo (carbidopa, levodopa and entacapone) ® can be given to patients receiving supplemental pyridoxine. Oral coadministration of 10-25 mg of pyridoxine hydrochloride (vitamin B6) with levodopa may reverse the effects of levodopa by increasing the rate of aromatic amino acid decarboxylation. Carbidopa inhibits this action of pyridoxine; therefore, Stalevo (carbidopa, levodopa and entacapone) ® can be given to patients receiving supplemental pyridoxine.
Effect of levodopa and carbidopa in Stalevo (carbidopa, levodopa and entacapone) ® on the metabolism of other drugs: Inhibition or induction effect of levodopa and carbidopa has not been investigated.
Effect of entacapone in Stalevo (carbidopa, levodopa and entacapone) ® on the metabolism of other drugs: Entacapone is unlikely to inhibit the metabolism of other drugs that are metabolized by major P450s including CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 µM; an oral 200 mg dose achieves a highest level of approximately 5 µM in people); these enzymes would therefore not be expected to be inhibited in clinical use. However, no information is available regarding the induction effect from entacapone.
Drugs that are highly protein bound (such as warfarin, salicylic acid, phenylbutazone, and diazepam):
Levodopa is bound to plasma protein only to a minor extent (about 10%-30%).
Carbidopa is approximately 36% bound to plasma protein.
Entacapone is highly protein bound (98%). In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
Of the ingredients in Stalevo (carbidopa, levodopa and entacapone) ® , levodopa is known to depress prolactin secretion and increase growth hormone levels.
Read the Stalevo Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 11/8/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Stalevo Information
Stalevo - User Reviews
Stalevo User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.